Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,323 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-881 and HyQvia in Healthy Adults

NCT06895967
Conditions
Healthy Volunteers
Interventions
TAK-881, HyQvia, SC Investigational Needle Sets
Biological · Device
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Type2 Diabetes
Interventions
Afrezza Inhalant Product
Drug
Lead sponsor
Model Clinical Research LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Peanut Allergy
Interventions
CNP-201, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
16 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Scottsdale, Arizona • Mountain View, California • Rolling Hills Estates, California + 5 more
Conditions
Colorectal Cancer
Interventions
Dacogen™ (decitabine), Vectibix® (panitumumab)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Histotripsy, Durvalumab, Biopsy
Device · Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Healthy Adult Immune Response
Interventions
VRC-HIVMAB095-00-AB (10E8VLS), VRC-HIVMAB075-00-AB (VRC07-523LS)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hypertension
Interventions
Azilsartan medoxomil with or without add-on chlorthalidone, Azilsartan medoxomil with or without add-on hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Ozark, Alabama • Tallassee, Alabama • Long Beach, California + 36 more
Conditions
Neuroectodermal Tumors, Primitive, Liver Neoplasms, Osteosarcoma, Other Childhood Cancers Using Cisplatin-based Regimens
Interventions
N-Acetylcysteine
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 21 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
HIV Medication Adherence, Methamphetamine Use, Sexual Risk, Poly-substance Use, HIV Infections
Interventions
Motivational Interviewing + Cognitive Behavioral Skills Training, Education Attention Control
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years and older · Male only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Results available

Energy Metabolism in Thyroidectomized Patients

NCT04782856
Conditions
Thyroid Goiter, Hypothyroidism, Thyroid Cancer
Interventions
Levothyroxine, Liothyronine, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 89 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Smoking Cessation for American Indians

NCT01106456
Conditions
Smoking Cessation
Interventions
All Nations Breath of Life (ANBL), Nontailored program (NT), Pharmacotherapy
Behavioral · Drug
Lead sponsor
Won Choi, PhD, MPH
Other
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
Kansas City, Kansas • Oklahoma City, Oklahoma
Conditions
Volume Loss (Soft Tissue Ptosis or Atrophy )
Interventions
Hyperdiluted Calcium Hydroxylapatite, Calcium hydroxylapatite, Calcium hydroxylapatite with integral lidocaine
Device
Lead sponsor
Kalpna Kay Durairaj, MD, FACS
Other
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pasadena, California
Conditions
Post Traumatic Stress Disorder
Interventions
Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Matching IV Placebo, Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm
Behavioral · Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
Interventions
Daclizumab, Mycophenolate mofetil (MMF), Prednisone, Tacrolimus, Ganciclovir, Valganciclovir, Trimethoprim and sulfamethoxazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Conditions
Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
Interventions
Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT
Other · Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
6,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 20 more
Completed Phase 2 Interventional Results available

ACT34-CMI -- Adult Autologous CD34+ Cells

NCT00300053
Conditions
Myocardial Ischemia
Interventions
CLBS14 (low-dose), CLBS14 (high-dose), placebo injection
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Conditions
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma
Interventions
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Palo Alto, California • Chicago, Illinois • Omaha, Nebraska + 3 more
Conditions
Genetics of Drug Metabolism
Interventions
Not listed
Lead sponsor
Companion Dx Reference Lab, LLC
Industry
Eligibility
18 Years and older
Enrollment
279,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Scottsdale, Arizona • Augusta, Arkansas • Arcadia, California + 38 more
Conditions
Foot Ulcer, Diabetic
Interventions
DERMASEAL, Plasma Film, Standard of Care
Combination Product · Biological · Other
Lead sponsor
Vitruvian Medical Devices, Inc.
Industry
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Fresno, California • South Miami, Florida • Boardman, Ohio + 1 more
Conditions
Autism
Interventions
divalproex sodium, Placebo
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
4 Years to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Louisville, Kentucky • Boston, Massachusetts
Conditions
Breast Cancer
Interventions
CDX-011, "Investigator's Choice" chemotherapy
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
24
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 19 more
Conditions
Posttraumatic Stress Disorder (PTSD), Anxiety, Depression - Major Depressive Disorder
Interventions
Mindful Self Compassion, Treatment as Usual (TAU)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pomona, California
Conditions
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
Interventions
MCLA-117 bispecific antibody
Drug
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Conditions
Graft vs. Host Disease
Interventions
Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Tampa, Florida